毒品管制局的大麻条例将制药公司推到国外,冒着美国在大麻药物方面的领导地位的风险。 DEA's marijuana regulations push pharmaceutical firms abroad, risking U.S. leadership in cannabis medicine.

缉毒署对大麻的严格管制正在将制药公司推向国外,威胁美国在大麻药物开发方面的领导地位。 The DEA's strict regulations on marijuana are pushing pharmaceutical companies abroad, threatening US leadership in cannabis-based medicine development. 批评者认为,官僚主义的拖延正在阻碍研究和创新,38个州已经将医用大麻合法化。 Critics argue that bureaucratic delays are hindering research and innovation, with 38 states having legalized medical marijuana. MMJ国际控股公司提起的诉讼凸显了这些问题,声称DEA非法拖延临床试验所需的批准。 A lawsuit by MMJ International Holdings highlights these issues, claiming the DEA is unlawfully delaying approvals needed for clinical trials. 该案可以决定美国制药创新的未来,可能的损失导致研究和生产的离岸外包。 The case could determine the future of American pharmaceutical innovation, with a potential loss leading to more offshoring of research and production.